Compare AbCellera Biologics Inc (ABCL) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Koninklijke Philips NV — how do they compare? AbCellera Biologics Inc trades at $9.71 (market cap $2.99B), while Koninklijke Philips NV trades at $26.59 (market cap $26.58B). The key difference: Koninklijke Philips NV is far larger — about 8.9× AbCellera Biologics Inc's market cap, and Koninklijke Philips NV pays a 3.75% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PHG | |
|---|---|---|
Market Cap | $2.99B | $26.58B |
Sector | Health | Health |
52-Week High | $9.76 | $32.91 |
52-Week Low | $2.78 | $25.02 |
Enterprise Value | $2.58B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
PHG trades at $26.94, up 0.79% with bullish technical signals and strong earnings beats in recent quarters. The company shows improving fundamentals with 2025 net income of $895M (5.01% margin) and positive cash flow trends. Recent news highlights Exor's increased stake flexibility and institutional buying interest, supporting positive sentiment despite some order timing challenges.
The outlook remains constructive with analyst consensus leaning positive (40.9% buy ratings) and improving profitability. Key risks include competitive pressures and macroeconomic headwinds, but solid execution and shareholder support provide stability for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
